|
12 Nov 2020 |
Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273)
|
|
12 Nov 2020 |
Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program
|
|
11 Nov 2020 |
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine
|
|
11 Nov 2020 |
CureVac Publishes Detailed Interim Phase 1 Data of its COVID-19 Vaccine Candidate, CVnCoV
|
|
11 Nov 2020 |
PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine
|
|
10 Nov 2020 |
Medigen and BlueWillow Biologics Partner to Develop Intranasal Vaccine for SARS-CoV-2
|
|
10 Nov 2020 |
Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate
|
|
09 Nov 2020 |
Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19
|
|
09 Nov 2020 |
Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore
|
|
09 Nov 2020 |
IMV’s T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck’s Keytruda® in PD-L1 Positive Patients with r/r DLBCL
|
|
09 Nov 2020 |
Istari Oncology Presents Positive Data from Phase 1 Study of PVSRIPO in Patients with Unresectable Treatment Refractory Melanoma at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
|
|
09 Nov 2020 |
ImmunityBio’s hAd5 COVID-19 Vaccine Candidate Stimulates Memory T-Cell Recall in Patients Infected with SARS-CoV-2
|
|
09 Nov 2020 |
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
|
|
06 Nov 2020 |
OSE Immunotherapeutics Provides COVID-19 Vaccine Update on CoVepiT, its Multi-Target and Long-Lasting Vaccine Candidate
|
|
02 Nov 2020 |
CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV
|
|
02 Nov 2020 |
First Healthy Volunteer Dosed in Symvivo’s Phase 1 Clinical Trial of bacTRL-Spike™, an Oral COVID-19 Vaccine Candidate
|
|
31 Oct 2020 |
Icosavax Launches COVID-19 Vaccine Program with Preclinical Data and $16.5 Million in New Funding
|
|
30 Oct 2020 |
OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19
|
|
29 Oct 2020 |
HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-202/HB-201 Alternating Vector Therapy to Treat Human Papillomavirus 16-Positive Cancers
|
|
27 Oct 2020 |
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
|
|
27 Oct 2020 |
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 2 Dose-Expansion Portion of Study Evaluating Investigational WT1 Immunotherapeutic Cancer Vaccine DSP-7888 (ombipepimut-S*) in Patients with Ovarian Cancer
|
|
27 Oct 2020 |
Department of Defense Awards Ology Bioservices Contract to Manufacture and Test Novel Live Attenuated Tularemia Vaccine Candidate
|
|
27 Oct 2020 |
TFF Pharmaceuticals Announces Positive Preclinical Results with University of Georgia Universal Influenza Vaccines
|
|
26 Oct 2020 |
PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 in Combination with Standard of Care Chemoradiotherapy in Advanced Cervical Cancer
|
|
26 Oct 2020 |
Advaxis’ ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial
|
